Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. It is also a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of tumor cells, known as somatostatin receptors, so that radiation can be delivered directly to the tumor cells and kill them. Giving sunitinib malate and lutetium Lu 177 dotatate in combination may be safer and more effective in treating pancreatic neuroendocrine tumors than giving either drug alone.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza nowotworu neuroendokrynnego trzustki (rozsiany lub niemożliwy do usunięcia chirurgicznie)
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia (ECOG 0-2)
- •Wystarczająca liczba białych krwinek (neutrofile ≥ 1000/mcL)
- •Wystarczająca liczba płytek krwi (≥ 75 000/mcL)
- •Prawidłowa funkcja wątroby i nerek
- •Pozytywny wynik badania PET/CT (wysoka ekspresja receptorów dla Lu 177)
- •Leczenie wcześniej nieznane lub progresja po maksymalnie jednej linii chemioterapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
City of Hope Comprehensive Cancer Center
Duarte, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
Memorial Hospital East
Shiloh, United States
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, United States
Siteman Cancer Center at West County Hospital
Creve Coeur, United States
Washington University School of Medicine
St Louis, United States
Siteman Cancer Center-South County
St Louis, United States
Siteman Cancer Center at Christian Hospital
St Louis, United States
University Health Network-Princess Margaret Hospital
Toronto, Canada
Trial contact
Site Public Contact
Jennifer B. Valerin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Nikolaos Trikalinos
PRINCIPAL_INVESTIGATOR
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.